ⓘ Emibetuzumab

                                     

ⓘ Emibetuzumab

Emibetuzumab is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC

This drug developed by Eli Lilly and company.